MedX Health Corp. (TSX-V: MDX) has received an order for 500 SIAScopeTM units for deployment on its DermSecureTM telemedicine platform from its exclusive Brazilian distributor, representing the single largest order in the company´s history, the company said.
MedX, headquartered in Mississauga, Ontario, is a medical device and software company focused on skin cancer with its SIAScopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility.
SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey.
MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
MedX Brasil is an independent licensee incorporated in Brazil, formed during 2019 to become the exclusive distributor of MedX Canada´s SIAscopy TM on DermSecure TM platform in Brazil. MedX Brasil has established a partnership with Oneway Diagnostics a specialist sales team in the Dermatology market in Brazil. MedX Brasil is responsible for marketing, educating, trade shows, financing activities to support the sales team at Oneway Diagnostics. https://www.medxbrasil.com.br/